GNT induction treatment for advanced nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a new drug combination called GNT given before standard chemoradiation for people with locally advanced nasopharyngeal cancer. It aims to improve treatment outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have stage III or IVB nasopharyngeal cancer that is either keratinizing or non-keratinizing squamous cell type.
- You are able to receive radiation and chemotherapy together as your main treatment.
- Your overall health allows you to perform daily activities (ECOG score 0-1).
- You have at least one tumor that can be measured, and your blood counts, kidney, and liver function are within certain normal ranges.
- You haven't had prior immunotherapy or targeted therapy for cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment plan for a specific type of advanced nasopharyngeal cancer. It combines chemotherapy and radiation to see if it can improve outcomes for people with high-risk stage III disease.
This trial tests a new treatment for advanced nasopharyngeal cancer. You will get chemotherapy and radiation, followed by maintenance therapy with an immunotherapy drug called toripalimab to help your immune system fight the cancer.
This trial compares two different chemotherapy combinations given before radiation for nasopharyngeal cancer. It is for patients with advanced but not metastatic disease who are in good overall health.
This trial tests a combination of three drugs as a first treatment for people with locally advanced nasopharyngeal cancer. It aims to see if the treatment shrinks tumors before standard therapy.
This trial tests two different chemotherapy combinations, each given with two extra drugs (one that targets cancer cells and one that boosts your immune system). It's for people with advanced nasopharyngeal cancer who haven't been treated yet, and it aims to see which combination works better.
This trial tests a new combination of an immunotherapy drug (tislelizumab) plus standard chemoradiotherapy for people with advanced nasopharyngeal carcinoma. It aims to find out if this combination is more effective than standard care alone.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.